Internal Medicine Department, Indiana University School of Medicine, Indianapolis, IN, U.S.A.
Department of Pathology, Indiana University School of Medicine, Carmel, IN, U.S.A.
Anticancer Res. 2020 Oct;40(10):5845-5851. doi: 10.21873/anticanres.14603.
Pancreatic mass sampling has historically been performed by endoscopic ultrasound-guided fine needle aspiration (EUS-FNA). However, its sensitivity has been reported to be within a wide range, which limits its reliability. Fine needle biopsy (FNB) has been shown to have superior diagnostic performance and is increasingly replacing fine needle aspiration. In FNA, 25 gauge (G) needles appear to outperform 22G. Data comparing these sizes in FNB platforms is limited. We aimed to prospectively compare the performance of 22G and 25G Franseen-tip core biopsy needles in the sampling of solid pancreatic lesions.
Patients who underwent EUS-FNB of pancreatic lesions at the Indiana University Hospital using 2 needle sizes: 25G (Study group) and 22G (Control group) using the Acquire needle (Boston Scientific Co., Natick, MA, USA) were enrolled. Needle choice was left to the discretion of the endosonographer. Tissue specimens were evaluated onsite, and underwent touch and smear and cellblock preparation. Specimens were independently evaluated by 2 expert cytopathologists blinded to diagnosis. Cytopathologists assessed cytological yield (on smears) and histological yield (on cellblock) using a validated scoring system reached by a consensus among our cytopathologists as we have previously published.
A total of 75 patients (42 males, median=65 years) underwent EUS-FNB during the study period (2017-2018): 50 using 25G and 25 using 22G needle. Diagnostic yield was numerically higher in 25G (98% vs. 88%, p=0.105). Number of passes for smears were similar, however the 25G group required additional passes for cell-block (1.6 vs. 0.4, p=0.001). 25G was used more frequently for pancreatic head and uncinate process sampling (70% vs. 52%, p=0.126). Four patients had self-limited adverse events in the 22G group, but none in the 25G group.
We report no difference in the diagnostic yield between 25G FNB vs. 22G sampling device with Franseen style tip, however, the 25G needle use was associated with the need of additional passes to collect a sufficient cell block.
胰腺肿块取样传统上由内镜超声引导下细针抽吸(EUS-FNA)进行。然而,其敏感性报告范围较宽,限制了其可靠性。细针活检(FNB)已被证明具有更高的诊断性能,并且越来越多地替代细针抽吸。在 FNA 中,25 号(G)针头似乎优于 22G。在 FNB 平台中比较这些大小的数据有限。我们旨在前瞻性比较 22G 和 25G 法式尖端芯活检针在胰腺实性病变取样中的性能。
在印第安纳大学医院,使用 2 种针头大小(25G [研究组]和 22G [对照组])进行 EUS-FNA 的胰腺病变患者入组。选择哪种针头由超声内镜医师决定。现场评估组织标本,并进行触诊和涂片以及细胞块制备。两名专家细胞病理学家独立评估标本,他们对诊断结果不知情。细胞病理学家使用我们之前发表的细胞病理学家共识达成的验证评分系统评估涂片的细胞学产量(在涂片上)和细胞块的组织学产量(在细胞块上)。
在研究期间(2017-2018 年),共有 75 名患者(42 名男性,中位年龄=65 岁)接受了 EUS-FNA:50 名患者使用 25G 针,25 名患者使用 22G 针。25G 的诊断产量略高(98%比 88%,p=0.105)。涂片的穿刺次数相似,但 25G 组需要更多的穿刺来获取细胞块(1.6 比 0.4,p=0.001)。25G 更常用于胰腺头部和钩突的取样(70%比 52%,p=0.126)。22G 组有 4 名患者出现自限性不良事件,但 25G 组无不良事件发生。
我们报告 25G FNB 与 22G 取样装置(带法式尖端)的诊断产量无差异,但 25G 针的使用与收集足够的细胞块需要更多的穿刺次数有关。